A study of the safety and tolerability of timolol administration by an eye implant in patients with glaucoma
Phase 1
Recruiting
- Conditions
- GlaucomaMedDRA version: 20.0Level: LLTClassification code: 10030856Term: Open-angle glaucoma Class: 10015919MedDRA version: 26.0Level: PTClassification code: 10048867Term: Pseudophakia Class: 10042613Therapeutic area: Diseases [C] - Eye Diseases [C11]
- Registration Number
- CTIS2024-511254-51-00
- Lead Sponsor
- Eyed Pharma
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 18
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method